1
|
Zhang Z, Ormiston K, Weinhold K, Schnell P, Kopec R, Lustberg M, Orchard T. Changes in Inflammatory Markers and Correlations with Serum Polyunsaturated Fatty Acids In Postmenopausal Women With Breast Cancer Undergoing Chemotherapy. J Acad Nutr Diet 2021. [DOI: 10.1016/j.jand.2021.06.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
2
|
Diéras V, Harbeck N, Joy A, Gelmon K, Ettl J, Verma S, Lu D, Gauthier E, Schnell P, Mori A, Rugo H, Finn R. PALOMA-2: Neutropenia (NP) patterns in patients (Pts) with estrogen receptor−positive (ER+)/human epidermal growth factor receptor 2−negative (HER2–) first-line advanced breast cancer (ABC) receiving palbociclib + letrozole (P+L). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx365.054] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
3
|
Rugo HS, Turner NC, Finn RS, Joy AA, Verma S, Harbeck N, Moulder S, Masuda N, Im YH, Zhang K, Kim S, Sun W, Schnell P, Huang-Bartlett C, Slamon D. Abstract P4-22-03: Palbociclib in combination with endocrine therapy in treatment-naive and previously treated elderly women with HR+, HER2– advanced breast cancer: a pooled analysis from randomized phase 2 and 3 studies. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-22-03] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: At least 40% of breast cancers are diagnosed in women ≥65 y old and most are hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-). Palbociclib (PAL) is an oral, small-molecule inhibitor of cyclin-dependent kinases 4 and 6. Randomized studies of PAL combined with endocrine therapy (ET) demonstrated significantly improved progression-free survival (PFS) in patients (pts) with treatment-naive and previously treated advanced breast cancer (ABC).
Methods: We evaluated the efficacy of PAL+ET vs ET alone in pts aged ≥65-74 and ≥75 y across multiple pivotal randomized phase 2 and 3 studies. Safety and pharmacokinetics (PK) data (blood samples collected from pts in phase 1/2 [PALOMA-1] and phase 1 studies [NCT00141297 and NCT00420056]) for PAL+ET were pooled and compared across age groups. Pts who had not received treatment for ABC were randomized to receive PAL+letrozole (LET) or LET alone/with placebo (PBO; PALOMA-1, open-label/PALOMA-2, double-blind). Pts who had progressed on prior ET were randomized to receive PAL+fulvestrant (FUL) or PBO+FUL (PALOMA-3, double-blind). The primary endpoint for these studies was investigator-assessed PFS. Safety assessments and blood counts occurred at baseline and every 2 weeks for the first 2 cycles and on day 1 of subsequent cycles.
Results: Among 872 pts treated with PAL+ET, 221 (25%) were aged ≥65-74 y and 83 (10%) were ≥75 y (PAL+LET: n=528, 162 and 56, respectively; PAL+FUL: n=347, 59 and 27). Median (range) treatment durations were 440 (1-1615) d, 502 (1-1615) d, and 459 (21-1404) d, respectively. Improvement in efficacy endpoints was seen with PAL+ET vs ET across all age groups (Table 1). Incidence of adverse events (AEs), serious AEs and discontinuations due to AEs were similar in the overall population (99%, 19%, 3%) and in pts aged ≥65-74 (99%, 25%, 5%) and ≥75 y (100%, 30%, 6%). Incidence of all grades and grade 3/4 neutropenia were also similar across age groups (overall: 67% and 54%; ≥65-74 y: 64% and 51%; ≥75 y: 77% and 60%). PK analysis showed no clinically relevant differences between arithmetic means, medians, and geometric means of the apparent oral clearance across age groups.
Conclusions: PAL in combination with ET is an effective and well-tolerated treatment option for elderly pts with HR+/HER2- endocrine-sensitive and -resistant ABC. A dose adjustment based on age is not required.
Sponsor: Pfizer
Table 1. PFS in pts ?65-74 and ?75 y (ITT populations)OverallAged ≥65-74 yAged ≥75 yPALOMA-1/PALOMA-2PAL+LET vs528 vs 303162 vs 9456 vs 26LET/LET+PBO,* nHR (95% CI);0.53 (0.44-0.64);0.66 (0.45-0.97);0.31 (0.16-0.61);1-sided P value<0.00010.01620.0002Median PFS (95% CI), mo24.4 (22.0-26.2) vs27.5 (24.2-NR) vsNR (19.2-NR) vs13.6 (11.1-16.4)21.8 (16.3-31.3)10.9 (4.9-24.9)PALOMA-3PAL+FUL vs347 vs 17459 vs 3727 vs 6FUL+PBO, nHR (95% CI);0.46 (0.36-0.59);0.25 (0.14-0.45);0.87 (0.27-2.79);1-sided P value<0.0001<0.00010.4074Median PFS (95% CI), mo9.5 (9.2-11.0) vs16.1 (12.0-NR) vs13.6 (7.5-NR) vs4.6 (3.5-5.6)3.7 (1.9-5.3)7.4 (1.9-NR)HR=hazard ratio; ITT=intent to treat; NR=not reached. *Does not include 5 pts from phase 1 of PALOMA-1.
Citation Format: Rugo HS, Turner NC, Finn RS, Joy AA, Verma S, Harbeck N, Moulder S, Masuda N, Im Y-H, Zhang K, Kim S, Sun W, Schnell P, Huang-Bartlett C, Slamon D. Palbociclib in combination with endocrine therapy in treatment-naive and previously treated elderly women with HR+, HER2– advanced breast cancer: a pooled analysis from randomized phase 2 and 3 studies [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-22-03.
Collapse
Affiliation(s)
- HS Rugo
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; David Geffen School of Medicine, Los Angeles, CA; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; University of Calgary, AB, Canada; Brustzentrum der Universität München (LMU), Munich, Germany; University of Texas, MD Anderson Cancer Center, Houston, TX; National Hospital Organization Osaka National Hospital, Osaka, Japan; Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Pfizer Inc, San Diego, CA; Pfizer Oncology, La Jolla, CA; Pfizer Inc, New York, NY; Pfizer Inc, Collegeville, PA
| | - NC Turner
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; David Geffen School of Medicine, Los Angeles, CA; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; University of Calgary, AB, Canada; Brustzentrum der Universität München (LMU), Munich, Germany; University of Texas, MD Anderson Cancer Center, Houston, TX; National Hospital Organization Osaka National Hospital, Osaka, Japan; Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Pfizer Inc, San Diego, CA; Pfizer Oncology, La Jolla, CA; Pfizer Inc, New York, NY; Pfizer Inc, Collegeville, PA
| | - RS Finn
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; David Geffen School of Medicine, Los Angeles, CA; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; University of Calgary, AB, Canada; Brustzentrum der Universität München (LMU), Munich, Germany; University of Texas, MD Anderson Cancer Center, Houston, TX; National Hospital Organization Osaka National Hospital, Osaka, Japan; Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Pfizer Inc, San Diego, CA; Pfizer Oncology, La Jolla, CA; Pfizer Inc, New York, NY; Pfizer Inc, Collegeville, PA
| | - AA Joy
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; David Geffen School of Medicine, Los Angeles, CA; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; University of Calgary, AB, Canada; Brustzentrum der Universität München (LMU), Munich, Germany; University of Texas, MD Anderson Cancer Center, Houston, TX; National Hospital Organization Osaka National Hospital, Osaka, Japan; Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Pfizer Inc, San Diego, CA; Pfizer Oncology, La Jolla, CA; Pfizer Inc, New York, NY; Pfizer Inc, Collegeville, PA
| | - S Verma
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; David Geffen School of Medicine, Los Angeles, CA; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; University of Calgary, AB, Canada; Brustzentrum der Universität München (LMU), Munich, Germany; University of Texas, MD Anderson Cancer Center, Houston, TX; National Hospital Organization Osaka National Hospital, Osaka, Japan; Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Pfizer Inc, San Diego, CA; Pfizer Oncology, La Jolla, CA; Pfizer Inc, New York, NY; Pfizer Inc, Collegeville, PA
| | - N Harbeck
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; David Geffen School of Medicine, Los Angeles, CA; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; University of Calgary, AB, Canada; Brustzentrum der Universität München (LMU), Munich, Germany; University of Texas, MD Anderson Cancer Center, Houston, TX; National Hospital Organization Osaka National Hospital, Osaka, Japan; Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Pfizer Inc, San Diego, CA; Pfizer Oncology, La Jolla, CA; Pfizer Inc, New York, NY; Pfizer Inc, Collegeville, PA
| | - S Moulder
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; David Geffen School of Medicine, Los Angeles, CA; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; University of Calgary, AB, Canada; Brustzentrum der Universität München (LMU), Munich, Germany; University of Texas, MD Anderson Cancer Center, Houston, TX; National Hospital Organization Osaka National Hospital, Osaka, Japan; Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Pfizer Inc, San Diego, CA; Pfizer Oncology, La Jolla, CA; Pfizer Inc, New York, NY; Pfizer Inc, Collegeville, PA
| | - N Masuda
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; David Geffen School of Medicine, Los Angeles, CA; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; University of Calgary, AB, Canada; Brustzentrum der Universität München (LMU), Munich, Germany; University of Texas, MD Anderson Cancer Center, Houston, TX; National Hospital Organization Osaka National Hospital, Osaka, Japan; Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Pfizer Inc, San Diego, CA; Pfizer Oncology, La Jolla, CA; Pfizer Inc, New York, NY; Pfizer Inc, Collegeville, PA
| | - Y-H Im
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; David Geffen School of Medicine, Los Angeles, CA; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; University of Calgary, AB, Canada; Brustzentrum der Universität München (LMU), Munich, Germany; University of Texas, MD Anderson Cancer Center, Houston, TX; National Hospital Organization Osaka National Hospital, Osaka, Japan; Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Pfizer Inc, San Diego, CA; Pfizer Oncology, La Jolla, CA; Pfizer Inc, New York, NY; Pfizer Inc, Collegeville, PA
| | - K Zhang
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; David Geffen School of Medicine, Los Angeles, CA; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; University of Calgary, AB, Canada; Brustzentrum der Universität München (LMU), Munich, Germany; University of Texas, MD Anderson Cancer Center, Houston, TX; National Hospital Organization Osaka National Hospital, Osaka, Japan; Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Pfizer Inc, San Diego, CA; Pfizer Oncology, La Jolla, CA; Pfizer Inc, New York, NY; Pfizer Inc, Collegeville, PA
| | - S Kim
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; David Geffen School of Medicine, Los Angeles, CA; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; University of Calgary, AB, Canada; Brustzentrum der Universität München (LMU), Munich, Germany; University of Texas, MD Anderson Cancer Center, Houston, TX; National Hospital Organization Osaka National Hospital, Osaka, Japan; Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Pfizer Inc, San Diego, CA; Pfizer Oncology, La Jolla, CA; Pfizer Inc, New York, NY; Pfizer Inc, Collegeville, PA
| | - W Sun
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; David Geffen School of Medicine, Los Angeles, CA; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; University of Calgary, AB, Canada; Brustzentrum der Universität München (LMU), Munich, Germany; University of Texas, MD Anderson Cancer Center, Houston, TX; National Hospital Organization Osaka National Hospital, Osaka, Japan; Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Pfizer Inc, San Diego, CA; Pfizer Oncology, La Jolla, CA; Pfizer Inc, New York, NY; Pfizer Inc, Collegeville, PA
| | - P Schnell
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; David Geffen School of Medicine, Los Angeles, CA; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; University of Calgary, AB, Canada; Brustzentrum der Universität München (LMU), Munich, Germany; University of Texas, MD Anderson Cancer Center, Houston, TX; National Hospital Organization Osaka National Hospital, Osaka, Japan; Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Pfizer Inc, San Diego, CA; Pfizer Oncology, La Jolla, CA; Pfizer Inc, New York, NY; Pfizer Inc, Collegeville, PA
| | - C Huang-Bartlett
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; David Geffen School of Medicine, Los Angeles, CA; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; University of Calgary, AB, Canada; Brustzentrum der Universität München (LMU), Munich, Germany; University of Texas, MD Anderson Cancer Center, Houston, TX; National Hospital Organization Osaka National Hospital, Osaka, Japan; Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Pfizer Inc, San Diego, CA; Pfizer Oncology, La Jolla, CA; Pfizer Inc, New York, NY; Pfizer Inc, Collegeville, PA
| | - D Slamon
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; David Geffen School of Medicine, Los Angeles, CA; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; University of Calgary, AB, Canada; Brustzentrum der Universität München (LMU), Munich, Germany; University of Texas, MD Anderson Cancer Center, Houston, TX; National Hospital Organization Osaka National Hospital, Osaka, Japan; Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Pfizer Inc, San Diego, CA; Pfizer Oncology, La Jolla, CA; Pfizer Inc, New York, NY; Pfizer Inc, Collegeville, PA
| |
Collapse
|
4
|
Diéras V, Rugo HS, Gelmon K, Finn RS, Cristofanilli M, Loi S, Colleoni M, Lu D, Gauthier E, Huang-Bartlett C, Turner NC, Schnell P. Abstract P4-22-07: Long-term safety of palbociclib in combination with endocrine therapy in treatment-naive and previously treated women with HR+ HER2– advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-22-07] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Palbociclib (PAL) is a selective and reversible oral cyclin-dependent kinase 4 and 6 inhibitor. Large randomized phase (ph) 2 and 3 trials showed significant improvement in progression-free survival (PFS) when PAL was combined with endocrine therapy (ET) vs ET alone in treatment (trt)-naive and previously treated hormone receptor?positive human epidermal growth factor receptor 2?negative (HR+ HER2–) advanced breast cancer (ABC) patients (pts). The median PFS with PAL+ET is >2 years as a first-line therapy for ABC and 11.2 mo in endocrine-resistant ABC. We evaluated the long-term safety in PALOMA-1, -2, and -3.
Methods: We analyzed the tolerability of PAL in combination with ET in 3 randomized trials. Pts untreated for ABC were randomized to receive PAL+letrozole (LET) vs LET alone in PALOMA-1 (ph 2, open-label; 1:1) or randomized to receive PAL+LET vs placebo (PBO)+LET in PALOMA-2 (ph 3, double-blind; 2:1). PALOMA-3 included pts who progressed on prior ET, randomized to receive PAL+fulvestrant (FUL) or PBO+FUL (ph 3, double-blind; 2:1). Safety assessments, including a complete blood count, were done at baseline, on D1 of each cycle, and on D14 of the first 2 cycles. We evaluated adverse events (AEs) by 6-mo intervals (out to 36 mo) and cumulatively (12-, 24-, and 36-mo time points), and assessed latency (event onset) of pertinent adverse drug reactions (ADRs) in all pts treated in PALOMA-1, -2, and -3.
Results: A total of 1352 pts were pooled for this analysis; 872 pts received PAL+ET (527 pts, PAL+LET; 345 pts, PAL+FUL). Median duration of trt was 421 days in PALOMA-1 (January 2015), 603 days in PALOMA-2 (February 2016), and 330 days in PALOMA-3 (July 2015). PAL+LET was received by 119 pts as first-line trt in PALOMA-1 and 2 for 24–<30 months and 11 pts were treated for >36 mo. PAL+FUL was received by 140 pts for >12 mo as second-line trt in PALOMA-3. The most commonly reported ADRs across all studies were neutropenia, fatigue, nausea, anemia, and leukopenia. The 6-mo-interval analyses of the most common (>15%) AEs (by preferred term [PT]) from PALOMA-1, -2, and -3 indicated that these AEs were reported with the highest frequency during the first 6-mo interval and typically decreased in incidence over time to 30–<36-mo; the most common hematologic AEs (clustered PTs) are shown (Table). The cumulative incidence of AEs after the first vs the second and third years showed similar frequencies of most AEs, including the most common ADRs.
Conclusions: Based on these long-term safety analyses, there is no evidence of specific cumulative or delayed toxicity resulting from prolonged trt with PAL+ET for HR+ HER2– ABC. This supports the ongoing investigation of PAL+ET in early breast cancer (NCT02513394).
Table. Pooled hematologic AEs: all grades and all causality clustered PTs reported for ≥10% of PAL+ET (LET/FUL)-treated ptsTime interval, mo0–<66–<1212–<1818–<2424–<3030–<36≥36Patients, N8726764912891192711TEAEs, % Neutropenia75.758.649.349.842.937.054.5Leukopenia40.027.416.711.87.611.118.2Anemia20.812.710.011.19.211.118.2Thrombocytopenia15.18.76.15.55.914.836.4TEAEs=treatment-emergent adverse events.
Sponsor: Pfizer.
Citation Format: Diéras V, Rugo HS, Gelmon K, Finn RS, Cristofanilli M, Loi S, Colleoni M, Lu D, Gauthier E, Huang-Bartlett C, Turner NC, Schnell P. Long-term safety of palbociclib in combination with endocrine therapy in treatment-naive and previously treated women with HR+ HER2– advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-22-07.
Collapse
Affiliation(s)
- V Diéras
- Institut Curie, Paris, France; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; British Columbia Cancer Agency, Vancouver, BC, Canada; David Geffen School of Medicine, Los Angeles, CA; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; Istituto Europeo di Oncologia, Milan, Italy; Pfizer Inc, La Jolla, CA; Pfizer Inc, Collegeville, PA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; Pfizer Inc, New York, NY
| | - HS Rugo
- Institut Curie, Paris, France; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; British Columbia Cancer Agency, Vancouver, BC, Canada; David Geffen School of Medicine, Los Angeles, CA; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; Istituto Europeo di Oncologia, Milan, Italy; Pfizer Inc, La Jolla, CA; Pfizer Inc, Collegeville, PA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; Pfizer Inc, New York, NY
| | - K Gelmon
- Institut Curie, Paris, France; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; British Columbia Cancer Agency, Vancouver, BC, Canada; David Geffen School of Medicine, Los Angeles, CA; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; Istituto Europeo di Oncologia, Milan, Italy; Pfizer Inc, La Jolla, CA; Pfizer Inc, Collegeville, PA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; Pfizer Inc, New York, NY
| | - RS Finn
- Institut Curie, Paris, France; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; British Columbia Cancer Agency, Vancouver, BC, Canada; David Geffen School of Medicine, Los Angeles, CA; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; Istituto Europeo di Oncologia, Milan, Italy; Pfizer Inc, La Jolla, CA; Pfizer Inc, Collegeville, PA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; Pfizer Inc, New York, NY
| | - M Cristofanilli
- Institut Curie, Paris, France; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; British Columbia Cancer Agency, Vancouver, BC, Canada; David Geffen School of Medicine, Los Angeles, CA; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; Istituto Europeo di Oncologia, Milan, Italy; Pfizer Inc, La Jolla, CA; Pfizer Inc, Collegeville, PA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; Pfizer Inc, New York, NY
| | - S Loi
- Institut Curie, Paris, France; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; British Columbia Cancer Agency, Vancouver, BC, Canada; David Geffen School of Medicine, Los Angeles, CA; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; Istituto Europeo di Oncologia, Milan, Italy; Pfizer Inc, La Jolla, CA; Pfizer Inc, Collegeville, PA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; Pfizer Inc, New York, NY
| | - M Colleoni
- Institut Curie, Paris, France; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; British Columbia Cancer Agency, Vancouver, BC, Canada; David Geffen School of Medicine, Los Angeles, CA; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; Istituto Europeo di Oncologia, Milan, Italy; Pfizer Inc, La Jolla, CA; Pfizer Inc, Collegeville, PA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; Pfizer Inc, New York, NY
| | - D Lu
- Institut Curie, Paris, France; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; British Columbia Cancer Agency, Vancouver, BC, Canada; David Geffen School of Medicine, Los Angeles, CA; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; Istituto Europeo di Oncologia, Milan, Italy; Pfizer Inc, La Jolla, CA; Pfizer Inc, Collegeville, PA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; Pfizer Inc, New York, NY
| | - E Gauthier
- Institut Curie, Paris, France; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; British Columbia Cancer Agency, Vancouver, BC, Canada; David Geffen School of Medicine, Los Angeles, CA; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; Istituto Europeo di Oncologia, Milan, Italy; Pfizer Inc, La Jolla, CA; Pfizer Inc, Collegeville, PA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; Pfizer Inc, New York, NY
| | - C Huang-Bartlett
- Institut Curie, Paris, France; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; British Columbia Cancer Agency, Vancouver, BC, Canada; David Geffen School of Medicine, Los Angeles, CA; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; Istituto Europeo di Oncologia, Milan, Italy; Pfizer Inc, La Jolla, CA; Pfizer Inc, Collegeville, PA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; Pfizer Inc, New York, NY
| | - NC Turner
- Institut Curie, Paris, France; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; British Columbia Cancer Agency, Vancouver, BC, Canada; David Geffen School of Medicine, Los Angeles, CA; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; Istituto Europeo di Oncologia, Milan, Italy; Pfizer Inc, La Jolla, CA; Pfizer Inc, Collegeville, PA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; Pfizer Inc, New York, NY
| | - P Schnell
- Institut Curie, Paris, France; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; British Columbia Cancer Agency, Vancouver, BC, Canada; David Geffen School of Medicine, Los Angeles, CA; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; Istituto Europeo di Oncologia, Milan, Italy; Pfizer Inc, La Jolla, CA; Pfizer Inc, Collegeville, PA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; Pfizer Inc, New York, NY
| |
Collapse
|
5
|
Verma S, DeMichele AM, Loi S, Ro J, Colleoni M, Iwata H, Harbeck N, Stearns V, Cristofanilli M, Huang Bartlett C, Schnell P, Zhang K, Thiele A, Turner NC, Rugo HS. Abstract P4-13-03: Updated safety from a double-blind phase 3 trial (PALOMA-3) of fulvestrant with placebo or with palbociclib in pre- and postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-13-03] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Endocrine therapy (ET) resistance remains a major clinical problem for patients (pts) with hormone receptor (HR+) breast cancer (BC). In PALOMA-3, palbociclib (P) combined with fulvestrant (F) demonstrated significant prolongation of progression-free survival (PFS) vs F plus placebo (PLB) in pre/peri and postmenopausal women with HR+/HER2– metastatic BC (MBC) whose disease progressed on prior ET (median PFS 9.2 vs 3.8 m; HR=0.422, P=0.0001).
Methods: In this double-blind phase 3 study, 521 pts with HR+/HER2– MBC were randomized 2:1 to receive P (125 mg/d orally for 3 weeks followed by 1 week off) and F (500 mg given per standard of care) or PLB plus F. Pre- and perimenopausal women also received goserelin. One previous line of chemotherapy (CT) for MBC was allowed. Safety assessments occurred at baseline and D1 of each cycle; blood counts occurred every 2 wks for the first 2 cycles and on D1 of subsequent cycles. As pts may have experienced multiple episodes of neutropenia during treatment, we analyzed all episodes in aggregate based on laboratory data per CTCAE4.0.
Results: The results reported here are from the data cutoff of Dec 2014, with a median follow-up of 5.6 m. Overall rate of any grade (G) and G3/4 AEs was 98/70% of pts in P+F vs 89/18% in PLB+F. The most commonly reported AEs in P+F (≥20%) were hematologic toxicities, fatigue, nausea, and headache. Per lab data, G3/G4 neutropenia occurred in 52.2/8.2%, G3/G4 leukopenia in 39.5/1.2%, G3/G4 anemia in 20.8/2.9% and G3/G4 thrombocytopenia in 2.1/1.2% of pts on P+F. Neutropenia occurred early, with a median onset time for first episode of ≥G3 neutropenia of 15 d (13–197) and median time from first dose to the lowest absolute neutrophil count (ANC) of 29 d (13–334). The median duration of ≥G3 episode was 7 d (1–35), suggesting that most pts can resume treatment after a 1-week cycle delay. A comparable proportion of any grade neutropenia was observed in pts with or without prior CT (prior CT 88.4% vs no prior CT 85.4%). There was no difference in the rate of G3/G4 neutropenia in the older pts (>65 yrs, 51% vs ≤65 yrs, 57%) in P+F arm. Concurrent G≥3 infections occurred in 1% of pts with G≥3 neutropenia (2/192 pts). Febrile neutropenia occurred in 0.6% of pts in both arms. 21% of pts had dose reductions and 45% had dose interruption due to neutropenia. Dose intensity was maintained at 89.7% for P. Serious adverse events (SAEs) were reported in 9.6% of pts on P+F and in 14% of pts on PLB+F. The most common SAEs on P+F were pulmonary embolism (0.9%) and pyrexia (0.9%). Safety analyses with longer follow-up (data cut off, March 2015) are ongoing and will be presented.
Conclusions: Findings suggest P+F has a favorable safety profile characterized mainly by asymptomatic hematologic toxicity. Overall SAE rates were low and comparable between the 2 arms. Palbociclib-related neutropenia differs from that seen with CT, consistent with proposed mechanism of action, in that it is not commonly associated with fever, and can be effectively managed by a dose interruption or cycle delay.
Funding: Pfizer, Inc.
Citation Format: Verma S, DeMichele AM, Loi S, Ro J, Colleoni M, Iwata H, Harbeck N, Stearns V, Cristofanilli M, Huang Bartlett C, Schnell P, Zhang K, Thiele A, Turner NC, Rugo HS. Updated safety from a double-blind phase 3 trial (PALOMA-3) of fulvestrant with placebo or with palbociclib in pre- and postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-13-03.
Collapse
Affiliation(s)
- S Verma
- Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Peter MacCallum Cancer Centre and University of Melbourne, East Melbourne and Parkville, Victoria, Australia; National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea; Istituto Europeo di Oncologia, Milano, Italy; Aichi Cancer Center Hospital, Nagoya, Japan; Brustzentrum der Universität München, Munchen, Germany; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD; Thomas Jefferson University, Philadelphia, PA; Pfizer Inc, New York City, NY; Pfizer Inc, San Diego, CA; Pfizer Inc, Cambridge, MA; Royal Marsden Hospital, London, United Kingdom; UCSF Medical Center at Mount Zion, San Francisco, CA
| | - AM DeMichele
- Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Peter MacCallum Cancer Centre and University of Melbourne, East Melbourne and Parkville, Victoria, Australia; National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea; Istituto Europeo di Oncologia, Milano, Italy; Aichi Cancer Center Hospital, Nagoya, Japan; Brustzentrum der Universität München, Munchen, Germany; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD; Thomas Jefferson University, Philadelphia, PA; Pfizer Inc, New York City, NY; Pfizer Inc, San Diego, CA; Pfizer Inc, Cambridge, MA; Royal Marsden Hospital, London, United Kingdom; UCSF Medical Center at Mount Zion, San Francisco, CA
| | - S Loi
- Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Peter MacCallum Cancer Centre and University of Melbourne, East Melbourne and Parkville, Victoria, Australia; National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea; Istituto Europeo di Oncologia, Milano, Italy; Aichi Cancer Center Hospital, Nagoya, Japan; Brustzentrum der Universität München, Munchen, Germany; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD; Thomas Jefferson University, Philadelphia, PA; Pfizer Inc, New York City, NY; Pfizer Inc, San Diego, CA; Pfizer Inc, Cambridge, MA; Royal Marsden Hospital, London, United Kingdom; UCSF Medical Center at Mount Zion, San Francisco, CA
| | - J Ro
- Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Peter MacCallum Cancer Centre and University of Melbourne, East Melbourne and Parkville, Victoria, Australia; National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea; Istituto Europeo di Oncologia, Milano, Italy; Aichi Cancer Center Hospital, Nagoya, Japan; Brustzentrum der Universität München, Munchen, Germany; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD; Thomas Jefferson University, Philadelphia, PA; Pfizer Inc, New York City, NY; Pfizer Inc, San Diego, CA; Pfizer Inc, Cambridge, MA; Royal Marsden Hospital, London, United Kingdom; UCSF Medical Center at Mount Zion, San Francisco, CA
| | - M Colleoni
- Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Peter MacCallum Cancer Centre and University of Melbourne, East Melbourne and Parkville, Victoria, Australia; National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea; Istituto Europeo di Oncologia, Milano, Italy; Aichi Cancer Center Hospital, Nagoya, Japan; Brustzentrum der Universität München, Munchen, Germany; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD; Thomas Jefferson University, Philadelphia, PA; Pfizer Inc, New York City, NY; Pfizer Inc, San Diego, CA; Pfizer Inc, Cambridge, MA; Royal Marsden Hospital, London, United Kingdom; UCSF Medical Center at Mount Zion, San Francisco, CA
| | - H Iwata
- Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Peter MacCallum Cancer Centre and University of Melbourne, East Melbourne and Parkville, Victoria, Australia; National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea; Istituto Europeo di Oncologia, Milano, Italy; Aichi Cancer Center Hospital, Nagoya, Japan; Brustzentrum der Universität München, Munchen, Germany; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD; Thomas Jefferson University, Philadelphia, PA; Pfizer Inc, New York City, NY; Pfizer Inc, San Diego, CA; Pfizer Inc, Cambridge, MA; Royal Marsden Hospital, London, United Kingdom; UCSF Medical Center at Mount Zion, San Francisco, CA
| | - N Harbeck
- Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Peter MacCallum Cancer Centre and University of Melbourne, East Melbourne and Parkville, Victoria, Australia; National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea; Istituto Europeo di Oncologia, Milano, Italy; Aichi Cancer Center Hospital, Nagoya, Japan; Brustzentrum der Universität München, Munchen, Germany; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD; Thomas Jefferson University, Philadelphia, PA; Pfizer Inc, New York City, NY; Pfizer Inc, San Diego, CA; Pfizer Inc, Cambridge, MA; Royal Marsden Hospital, London, United Kingdom; UCSF Medical Center at Mount Zion, San Francisco, CA
| | - V Stearns
- Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Peter MacCallum Cancer Centre and University of Melbourne, East Melbourne and Parkville, Victoria, Australia; National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea; Istituto Europeo di Oncologia, Milano, Italy; Aichi Cancer Center Hospital, Nagoya, Japan; Brustzentrum der Universität München, Munchen, Germany; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD; Thomas Jefferson University, Philadelphia, PA; Pfizer Inc, New York City, NY; Pfizer Inc, San Diego, CA; Pfizer Inc, Cambridge, MA; Royal Marsden Hospital, London, United Kingdom; UCSF Medical Center at Mount Zion, San Francisco, CA
| | - M Cristofanilli
- Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Peter MacCallum Cancer Centre and University of Melbourne, East Melbourne and Parkville, Victoria, Australia; National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea; Istituto Europeo di Oncologia, Milano, Italy; Aichi Cancer Center Hospital, Nagoya, Japan; Brustzentrum der Universität München, Munchen, Germany; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD; Thomas Jefferson University, Philadelphia, PA; Pfizer Inc, New York City, NY; Pfizer Inc, San Diego, CA; Pfizer Inc, Cambridge, MA; Royal Marsden Hospital, London, United Kingdom; UCSF Medical Center at Mount Zion, San Francisco, CA
| | - C Huang Bartlett
- Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Peter MacCallum Cancer Centre and University of Melbourne, East Melbourne and Parkville, Victoria, Australia; National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea; Istituto Europeo di Oncologia, Milano, Italy; Aichi Cancer Center Hospital, Nagoya, Japan; Brustzentrum der Universität München, Munchen, Germany; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD; Thomas Jefferson University, Philadelphia, PA; Pfizer Inc, New York City, NY; Pfizer Inc, San Diego, CA; Pfizer Inc, Cambridge, MA; Royal Marsden Hospital, London, United Kingdom; UCSF Medical Center at Mount Zion, San Francisco, CA
| | - P Schnell
- Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Peter MacCallum Cancer Centre and University of Melbourne, East Melbourne and Parkville, Victoria, Australia; National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea; Istituto Europeo di Oncologia, Milano, Italy; Aichi Cancer Center Hospital, Nagoya, Japan; Brustzentrum der Universität München, Munchen, Germany; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD; Thomas Jefferson University, Philadelphia, PA; Pfizer Inc, New York City, NY; Pfizer Inc, San Diego, CA; Pfizer Inc, Cambridge, MA; Royal Marsden Hospital, London, United Kingdom; UCSF Medical Center at Mount Zion, San Francisco, CA
| | - K Zhang
- Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Peter MacCallum Cancer Centre and University of Melbourne, East Melbourne and Parkville, Victoria, Australia; National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea; Istituto Europeo di Oncologia, Milano, Italy; Aichi Cancer Center Hospital, Nagoya, Japan; Brustzentrum der Universität München, Munchen, Germany; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD; Thomas Jefferson University, Philadelphia, PA; Pfizer Inc, New York City, NY; Pfizer Inc, San Diego, CA; Pfizer Inc, Cambridge, MA; Royal Marsden Hospital, London, United Kingdom; UCSF Medical Center at Mount Zion, San Francisco, CA
| | - A Thiele
- Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Peter MacCallum Cancer Centre and University of Melbourne, East Melbourne and Parkville, Victoria, Australia; National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea; Istituto Europeo di Oncologia, Milano, Italy; Aichi Cancer Center Hospital, Nagoya, Japan; Brustzentrum der Universität München, Munchen, Germany; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD; Thomas Jefferson University, Philadelphia, PA; Pfizer Inc, New York City, NY; Pfizer Inc, San Diego, CA; Pfizer Inc, Cambridge, MA; Royal Marsden Hospital, London, United Kingdom; UCSF Medical Center at Mount Zion, San Francisco, CA
| | - NC Turner
- Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Peter MacCallum Cancer Centre and University of Melbourne, East Melbourne and Parkville, Victoria, Australia; National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea; Istituto Europeo di Oncologia, Milano, Italy; Aichi Cancer Center Hospital, Nagoya, Japan; Brustzentrum der Universität München, Munchen, Germany; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD; Thomas Jefferson University, Philadelphia, PA; Pfizer Inc, New York City, NY; Pfizer Inc, San Diego, CA; Pfizer Inc, Cambridge, MA; Royal Marsden Hospital, London, United Kingdom; UCSF Medical Center at Mount Zion, San Francisco, CA
| | - HS Rugo
- Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; University of Pennsylvania, Philadelphia, PA; Peter MacCallum Cancer Centre and University of Melbourne, East Melbourne and Parkville, Victoria, Australia; National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea; Istituto Europeo di Oncologia, Milano, Italy; Aichi Cancer Center Hospital, Nagoya, Japan; Brustzentrum der Universität München, Munchen, Germany; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD; Thomas Jefferson University, Philadelphia, PA; Pfizer Inc, New York City, NY; Pfizer Inc, San Diego, CA; Pfizer Inc, Cambridge, MA; Royal Marsden Hospital, London, United Kingdom; UCSF Medical Center at Mount Zion, San Francisco, CA
| |
Collapse
|
6
|
Ro J, Im SA, Masuda N, Im YH, Inoue K, Rai Y, Nakamura R, Kim J, Zhang K, Giorgetti C, Schnell P, Huang Bartlett C, Iwata H. 53O_PR Efficacy and safety of palbociclib plus fulvestrant in Asian women with hormone receptor-positive (HR+)/human epidermal growth factor-2 negative (HER2-) metastatic breast cancer (MBC) that progressed on prior endocrine therapy (ET). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv519.02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
7
|
Finn R, Crown J, Ettl J, Pinter T, Schmidt M, Huang-Bartlett C, Schnell P, Kim S, Randolph S, Wang K, Slamon D. Clinical Patterns of Palbociclib Associated Neutropenia in the Paloma-1/Trio-18 Trial. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu329.17] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
8
|
Donner B, Schnell P, Zenz M. [Indications and limits of nerve block techniques]. Z Arztl Fortbild Qualitatssich 1998; 92:29-33. [PMID: 9553210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Repetitive nerve blocks as a monotherapeutic treatment are loosing importance in the therapy of chronic pain. Such invasive methods for pain reduction are just one strategy in the interdisciplinary and multimodal planning of pain therapy. They are mostly used in special indications, e.g. reflex sympathetic dystrophy neurolysis in S3-S5 localized cancer pain. Premises for an invasive pain therapy are the patient's knowledge and agreement concerning this method. Furthermore, it is necessary for the physician to know the typical complications of the invasive treatment and to be able to manage them. It is recommended to document the pain course.
Collapse
Affiliation(s)
- B Donner
- Klinik für Anaesthesiologie, Intensiv- und Schmerztherapie, Universitätsklinik Bochum
| | | | | |
Collapse
|
9
|
Holdener EE, Schnell P, Spieler P, Senn H. In vitro effect of interferon-alpha on human granulocyte/macrophage progenitor cells and human clonogenic tumor cells. Recent Results Cancer Res 1984; 94:205-19. [PMID: 6494582 DOI: 10.1007/978-3-642-82295-7_22] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
10
|
Schnell P, Courouce AM, Opolon P, Darnis F. [The "e" antigen system in HBs antigen carriers (author's transl)]. Nouv Presse Med 1978; 7:3105-8. [PMID: 103075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Antigen e and its antibody were sought by radial immunodiffusion in 86 carriers of HBs antigen observed over a period of one year. The antigen was found in 3 cases out of 30 with acute viral hepatitis, 11 cases out of 33 with chronic active hepatitis, 1 case out of 6 with chronic persistent hepatitis and 1 out of 6 healthy carriers. It was not found in the serum of 6 patients with fulminating hepatitis. The presence of antigen e is associated with high titers of circulating HBs antigens (p less than 0,001). In this group, no difference in the course of the disease was found in cases of chronic active hepatitis with HBs antigen, according to the presence or absence of antigen e or its antibody.
Collapse
|